Literature DB >> 12646948

Prospective analysis of minimal bone marrow infiltration in pediatric Burkitt's lymphomas by long-distance polymerase chain reaction for t(8;14)(q24;q32).

L Mussolin1, K Basso, M Pillon, E S D'Amore, A Lombardi, L Luzzatto, L Zanesco, A Rosolen.   

Abstract

The chromosomal translocation t(8;14)(q24;q32) represents a characteristic marker for Burkitt's lymphoma (BL). This translocation involves the MYC oncogene on chromosome 8 and the immunoglobulin heavy-chain (IgH) locus on chromosome 14. Since the translocation does not produce a fusion gene, we established a long-distance polymerase chain reaction (LD-PCR) assay that can detect the t(8;14) at the genomic level. The sensitivity of the LD-PCR was 10(-4). We used the LD-PCR assay to prospectively study 78 BL patients and found a specific PCR product in 52 of them. Among the 52 positive patients, we could test both the tumor and the bone marrow (BM) at diagnosis in 33 and determined the prevalence of minimal disseminated disease (MDD) at diagnosis. In 12/33 patients, BM was positive by LD-PCR and in 10 of them we conducted a study of minimal residual disease (MRD). Eight out of 10 children showed a clearance of MRD after one cycle of chemotherapy. The only two patients who did not achieve a negative MRD status died of disease progression. The comparative analysis of sensitivity of BM aspirate, BM biopsy and LD-PCR in t(8;14)-positive patients demonstrated a superiority of the molecular method in the assessment of MDD. The LD-PCR for t(8;14) is an important tool to study minimal BM infiltration at diagnosis and to determine its response kinetics in BL.

Entities:  

Mesh:

Year:  2003        PMID: 12646948     DOI: 10.1038/sj.leu.2402828

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  5 in total

1.  Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma: a children's oncology group report.

Authors:  Bruce Shiramizu; Stanton Goldman; Ian Kusao; Melissa Agsalda; James Lynch; Lynette Smith; Lauren Harrison; Erin Morris; Thomas G Gross; Warren Sanger; Sherrie Perkins; Mitchell S Cairo
Journal:  Br J Haematol       Date:  2011-04-18       Impact factor: 6.998

2.  Revised International Pediatric Non-Hodgkin Lymphoma Staging System.

Authors:  Angelo Rosolen; Sherrie L Perkins; C Ross Pinkerton; R Paul Guillerman; John T Sandlund; Catherine Patte; Alfred Reiter; Mitchell S Cairo
Journal:  J Clin Oncol       Date:  2015-05-04       Impact factor: 44.544

3.  Development and Clinical Validation of a Large Fusion Gene Panel for Pediatric Cancers.

Authors:  Fengqi Chang; Fumin Lin; Kajia Cao; Lea F Surrey; Richard Aplenc; Rochelle Bagatell; Adam C Resnick; Mariarita Santi; Phillip B Storm; Sarah K Tasian; Angela J Waanders; Stephen P Hunger; Marilyn M Li
Journal:  J Mol Diagn       Date:  2019-06-27       Impact factor: 5.568

Review 4.  Treatment of adolescents with aggressive B-cell malignancies: the pediatric experience.

Authors:  Jonas Lange; Birgit Burkhardt
Journal:  Curr Hematol Malig Rep       Date:  2013-09       Impact factor: 3.952

5.  Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children's oncology group.

Authors:  Elaine Coustan-Smith; John T Sandlund; Sherrie L Perkins; Helen Chen; Myron Chang; Minnie Abromowitch; Dario Campana
Journal:  J Clin Oncol       Date:  2009-06-22       Impact factor: 44.544

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.